CR20160235A - Tienopirimidinas como inhibidores mknk1 y mknk2 - Google Patents

Tienopirimidinas como inhibidores mknk1 y mknk2

Info

Publication number
CR20160235A
CR20160235A CR20160235A CR20160235A CR20160235A CR 20160235 A CR20160235 A CR 20160235A CR 20160235 A CR20160235 A CR 20160235A CR 20160235 A CR20160235 A CR 20160235A CR 20160235 A CR20160235 A CR 20160235A
Authority
CR
Costa Rica
Prior art keywords
compounds
tienopirimidins
mknk1
mknk2
inhibitors
Prior art date
Application number
CR20160235A
Other languages
English (en)
Inventor
Ulrich Klar
Lars Wortmann
Georg Kettschau
Keith Graham
Anja Richter
Philip Lienau
Florian Puehler
Kirstin Petersen
Franziska Siegel
Detlev Sülzle
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CR20160235A publication Critical patent/CR20160235A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compuestos de tienopirimidina sustituidos de la fórmula general (I) que se describen y definen en la presente, métodos de preparación de dichos compuestos, compuestos intermediarios de utilidad para preparar dichos compuestos, composiciones y combinaciones farmacéuticas que comprenden dichos compuestos y el uso de dichos compuestos en la elaboración de una composición farmacéutica para el tratamiento o la profilaxis de una enfermedad, en particular de un trastorno hiperproliferativo y/o de angiogénesis, como agente único o en combinación con otros ingredientes activos.
CR20160235A 2013-11-20 2016-05-20 Tienopirimidinas como inhibidores mknk1 y mknk2 CR20160235A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13193665 2013-11-20
EP14174731 2014-06-27
PCT/EP2014/074722 WO2015074986A1 (en) 2013-11-20 2014-11-17 Thienopyrimidines as mknk1 and mknk2 inhibitors

Publications (1)

Publication Number Publication Date
CR20160235A true CR20160235A (es) 2016-07-20

Family

ID=52000798

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20160235A CR20160235A (es) 2013-11-20 2016-05-20 Tienopirimidinas como inhibidores mknk1 y mknk2

Country Status (22)

Country Link
US (1) US20160297833A1 (es)
EP (1) EP3071577A1 (es)
JP (1) JP2016539113A (es)
KR (1) KR20160086404A (es)
CN (1) CN106061980A (es)
AP (1) AP2016009225A0 (es)
AU (1) AU2014352066A1 (es)
BR (1) BR112016011472A2 (es)
CA (1) CA2930873A1 (es)
CL (1) CL2016001218A1 (es)
CR (1) CR20160235A (es)
CU (1) CU20160072A7 (es)
DO (1) DOP2016000118A (es)
EA (1) EA201600398A1 (es)
IL (1) IL245404A0 (es)
MX (1) MX2016006631A (es)
PE (1) PE20160593A1 (es)
PH (1) PH12016500931A1 (es)
TN (1) TN2016000194A1 (es)
TW (1) TW201605867A (es)
UY (1) UY35848A (es)
WO (1) WO2015074986A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
BR112018008714A2 (pt) * 2015-10-29 2018-10-30 Effector Therapeutics Inc inibidores de isoindolina, azaisoindolina, dihidroindenona e dihidroazaindenona da mnk1 e mnk2
CA3002558A1 (en) * 2015-10-29 2017-05-04 Effector Therapeutics, Inc. Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2
WO2017087808A1 (en) 2015-11-20 2017-05-26 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
CN106727587A (zh) * 2016-11-28 2017-05-31 李娜 一种治疗心律失常的药物组合物
EP3571206A1 (en) 2017-01-20 2019-11-27 Bayer Pharma Aktiengesellschaft Substituted imidazopyridinpyrimidines
EA201991894A1 (ru) 2017-02-14 2020-02-05 Эффектор Терапьютикс, Инк. ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
JP2022505846A (ja) 2018-10-24 2022-01-14 イーフェクター セラピューティクス， インコーポレイテッド Ｍｎｋ阻害剤の結晶形態
CN110981903A (zh) * 2019-11-28 2020-04-10 南京正济医药研究有限公司 一种艾日布林中间体化合物提高光学纯度的精制方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1401840A4 (en) * 2001-04-30 2007-05-16 Bayer Corp NEW 4-AMINO-5,6-SUBSTITUTED THIOPHENO 2,3 D | PYRIMIDINE
DE60320933D1 (de) * 2002-01-10 2008-06-26 Bayer Healthcare Ag Rho-kinase inhibitoren
WO2005010008A1 (en) * 2003-07-24 2005-02-03 Bayer Pharmaceuticals Corporation Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders
US8207172B2 (en) * 2004-08-20 2012-06-26 Bayer Intellectual Property Gmbh Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders
UY29161A1 (es) * 2004-10-15 2006-04-28 Bayer Pharmaceuticals Corp Nuevos heterociclos
US20100143341A1 (en) * 2005-06-22 2010-06-10 Develogen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
WO2007059905A2 (en) * 2005-11-25 2007-05-31 Develogen Aktiengesellschaft Thienopyrimidines treating inflammatory diseases
MX2012009735A (es) * 2010-02-26 2012-09-12 Boehringer Ingelheim Int 4-[cicloalquiloxi (hetero) arilamino] tieno [2,3-d] pirimidinas que tienen actividad inhibitoria de mnk1/mnk2 para composiciones farmaceuticas.
WO2013106535A1 (en) * 2012-01-10 2013-07-18 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US9540392B2 (en) * 2012-05-21 2017-01-10 Bayer Pharma Aktiengesellschaft Thienopyrimidines
CA2873971A1 (en) * 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyrimidines
CN104470931B (zh) * 2012-05-21 2016-10-26 拜耳医药股份有限公司 取代的苯并噻吩并嘧啶
WO2014118229A1 (en) * 2013-02-01 2014-08-07 Bayer Pharma Aktiengesellschaft Substituted thienopyrimidines and pharmaceutical use thereof
MX2016000163A (es) * 2013-07-08 2016-04-15 Bayer Pharma AG Pirazolpiridinas sustituidas.

Also Published As

Publication number Publication date
TW201605867A (zh) 2016-02-16
WO2015074986A1 (en) 2015-05-28
PH12016500931A1 (en) 2016-06-27
EP3071577A1 (en) 2016-09-28
US20160297833A1 (en) 2016-10-13
AP2016009225A0 (en) 2016-05-31
PE20160593A1 (es) 2016-07-13
KR20160086404A (ko) 2016-07-19
IL245404A0 (en) 2016-06-30
AU2014352066A1 (en) 2016-05-26
TN2016000194A1 (en) 2017-10-06
UY35848A (es) 2015-06-30
DOP2016000118A (es) 2016-06-30
BR112016011472A2 (pt) 2017-09-26
EA201600398A1 (ru) 2016-10-31
CA2930873A1 (en) 2015-05-28
CL2016001218A1 (es) 2016-12-16
JP2016539113A (ja) 2016-12-15
CU20160072A7 (es) 2016-10-28
CN106061980A (zh) 2016-10-26
MX2016006631A (es) 2016-08-17

Similar Documents

Publication Publication Date Title
ECSP17007538A (es) 2-(morfolin-4-il)-1,7-naftiridinas
CR20160235A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
DOP2017000137A (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo.
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
CO2017005968A2 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
UY33598A (es) Imidazopiridazinas sustituidas
DOP2016000253A (es) Nuevos compuestos
NI201500118A (es) Imidazopiridazinas sustituidas
ECSP14013231A (es) Imidazopiridazinas sustituidas con amino
NI201600006A (es) Pirazolo-piridinaminas sustituidas
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
UY37444A (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y su uso
UY36983A (es) Pirazolopiridinaminas sustituidas
UY37032A (es) Compuestos de heteroarilbenzimidazol
UY34630A (es) Imidazopiridazinas sustituidas con amino